Savara (SVRA) Current Leases (2016 - 2018)

Savara (SVRA) reported Current Leases of $41000.0 for Q4 2018, down 84.53% year-over-year from $265000.0 in Q4 2017, and down 87.11% on a QoQ basis from $318000.0 in Q3 2018.

Savara (SVRA) has 3 years of Current Leases data on file, last reported at $41000.0 in Q4 2018.

  • Quarterly Current Leases fell 84.53% year-over-year to $41000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $41000.0 (down 84.53% YoY) and the FY2018 annual result came in at $41000.0, down 84.53% from the prior year.
  • Current Leases eased to $41000.0 in Q4 2018 per SVRA's latest filing, from $318000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $719000.0 in Q2 2017 and bottomed at $21000.0 in Q1 2018.
  • The 3-year median for Current Leases is $291500.0 (2017), against an average of $298625.0.
  • Peak annual rise in Current Leases reached 20.0% in 2018, while the deepest fall reached 84.53% in 2018.
  • Tracing SVRA's Current Leases over 3 years: stood at $442000.0 in 2016, then plunged by 40.05% to $265000.0 in 2017, then slumped by 84.53% to $41000.0 in 2018.
  • Per Business Quant, the three latest SVRA Current Leases figures stand at $41000.0 (Q4 2018), $318000.0 (Q3 2018), and $318000.0 (Q2 2018).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 83,991.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 7.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 720.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 45.66 Mn
10 Savara 1.30 Bn 1.30 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 41,000.00
Sep 30, 2018 318,000.00
Jun 30, 2018 318,000.00
Mar 31, 2018 21,000.00
Dec 31, 2017 265,000.00
Sep 30, 2017 265,000.00
Jun 30, 2017 719,000.00
Dec 31, 2016 442,000.00